---

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

---

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported) September 28, 2004

 

ANTARES PHARMA, INC.

(Exact Name of Registrant as Specified in Charter)

 

Minnesota		0-20945		41-1350192
(State or Other Jurisdiction of		(Commission File Number)		(IRS Employer
Incorporation)				Identification No.)

 

707 Eagleview Boulevard, Suite 414, Exton, PA		19341
(Address of Principal Executive Offices)		(Zip Code)

 

Registrant’s telephone number, including area code (610) 458-6200

 

n/a

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

---

---

Item 7.01.

Regulation FD Disclosure.

 

Antares Pharma, Inc. today will make a presentation at the UBS Global Life Sciences Conference regarding its operations and business. The PowerPoint slide presentation to be used during Antares Pharma’s presentation at this conference is furnished as Exhibit 99.1.

 

Item 9.01.

Financial Statements and Exhibits.

 

(c) Exhibits

 

99.1		PowerPoint Slides (furnished)

 

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 28, 2004						By		/s/    LAWRENCE M. CHRISTIAN
								Lawrence M. Christian
						Its		Chief Financial Officer